JP2019528082A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528082A5 JP2019528082A5 JP2019517135A JP2019517135A JP2019528082A5 JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5 JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019517135 A JP2019517135 A JP 2019517135A JP 2019528082 A5 JP2019528082 A5 JP 2019528082A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antibody
- fusion protein
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021088589A JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610404956 | 2016-06-08 | ||
| CN201610404956.7 | 2016-06-08 | ||
| PCT/CN2017/087620 WO2017211321A1 (zh) | 2016-06-08 | 2017-06-08 | 增强激动型抗体活性的抗体重链恒定区序列 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088589A Division JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019528082A JP2019528082A (ja) | 2019-10-10 |
| JP2019528082A5 true JP2019528082A5 (https=) | 2019-11-21 |
Family
ID=60578403
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019517135A Pending JP2019528082A (ja) | 2016-06-08 | 2017-06-08 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2021088589A Pending JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A Active JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021088589A Pending JP2021143186A (ja) | 2016-06-08 | 2021-05-26 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
| JP2024087108A Active JP7809372B2 (ja) | 2016-06-08 | 2024-05-29 | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12145993B2 (https=) |
| EP (1) | EP3470424B1 (https=) |
| JP (3) | JP2019528082A (https=) |
| CN (2) | CN107474136B (https=) |
| WO (1) | WO2017211321A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2990885A1 (en) * | 2015-06-30 | 2017-01-05 | Sanford-Burnham Medical Research Institute | Btla fusion protein agonists and uses thereof |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| JP7774283B2 (ja) * | 2017-12-19 | 2025-11-21 | ザ ロックフェラー ユニバーシティー | エフェクター機能を改良したヒトＩｇＧのＦｃ領域改変体 |
| CN111788227B (zh) * | 2017-12-27 | 2025-02-25 | 百时美施贵宝公司 | 抗cd40抗体及其用途 |
| CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
| CN110144009B (zh) * | 2018-02-14 | 2020-01-21 | 上海洛启生物医药技术有限公司 | Cd47单域抗体及其用途 |
| EP3887397A1 (en) * | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥（蘇州）有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
| WO2020207470A1 (zh) * | 2019-04-10 | 2020-10-15 | 南开大学 | 抗cd40抗体及其用途 |
| CN110981958B (zh) * | 2019-08-23 | 2020-10-20 | 四川大学华西医院 | 一种pd-l1抗体 |
| CN112592404B (zh) * | 2019-09-20 | 2023-07-25 | 上海交通大学医学院 | 抗体活性改造及其筛选方法 |
| KR20220109436A (ko) | 2019-12-03 | 2022-08-04 | 에보텍 인터내셔널 게엠베하 | 인터페론-결합된 항원 결합 단백질 및 이의 용도 |
| CN110862455B (zh) * | 2019-12-03 | 2021-12-21 | 源道隆（苏州）医学科技有限公司 | 可结合cd47的多肽及其应用 |
| JP7836088B2 (ja) * | 2019-12-03 | 2026-03-26 | 上海交通大学医学院 | ＦｃγＲＩＩＢ親和性が増強された抗体Ｆｃ領域 |
| BR112022023989A2 (pt) | 2020-05-26 | 2023-02-07 | Boehringer Ingelheim Int | Anticorpos anti-pd-1 |
| CN114591428B (zh) * | 2020-12-04 | 2024-05-28 | 上海交通大学医学院 | 抗Dsg1抗体及其应用 |
| KR102671409B1 (ko) * | 2021-03-02 | 2024-05-31 | 진화섭 | Cd30을 발현하는 세포에 독성을 나타내는 재조합 단백질 및 이를 유효성분으로 포함하는 암의 치료용 약학적 조성물 |
| CN118339300A (zh) * | 2024-01-02 | 2024-07-12 | 江苏集萃药康生物科技股份有限公司 | 产生人源化抗体的动物模型及其构建方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| CN103172731A (zh) * | 2004-07-15 | 2013-06-26 | 赞科股份有限公司 | 优化的Fc变体 |
| JP5188804B2 (ja) * | 2004-08-03 | 2013-04-24 | トランステック ファーマ，インコーポレイティド | Ｒａｇｅ融合タンパク質及びその使用方法 |
| KR20070090036A (ko) * | 2004-12-22 | 2007-09-04 | 센토코 인코포레이티드 | Ｇｌｐ-1 작용제, 조성물, 방법 및 용도 |
| WO2007067828A2 (en) * | 2005-10-24 | 2007-06-14 | Centocor, Inc. | Glp-2 mimetibodies, polypeptides, compositions, methods and uses |
| CA2759146C (en) * | 2009-04-20 | 2017-06-13 | Kyowa Kirin Co., Ltd. | Agonist anti-cd40 antibody |
| CA2822366A1 (en) * | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| CN112812184A (zh) * | 2011-02-25 | 2021-05-18 | 中外制药株式会社 | FcγRIIb特异性Fc抗体 |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| JP6322411B2 (ja) * | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
| SG10201805584YA (en) * | 2012-02-24 | 2018-08-30 | Chugai Pharmaceutical Co Ltd | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA FcγRIIB |
| US9890378B2 (en) * | 2012-05-11 | 2018-02-13 | Merck Sharp & Dohme Corp. | Surface anchored light chain bait antibody display system |
| TW202237660A (zh) * | 2012-08-24 | 2022-10-01 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| AU2013337903B2 (en) * | 2012-10-30 | 2018-08-16 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| SMT201800503T1 (it) * | 2013-03-18 | 2018-11-09 | Janssen Pharmaceuticals Inc | Anticorpi anti-cd (ox40) umanizzati e loro usi |
| US10669328B2 (en) * | 2013-11-12 | 2020-06-02 | Ogd2 Pharma | Human IgG1 derived antibody with pro-apoptotic activity |
| EP3099717B1 (en) * | 2014-01-31 | 2019-03-27 | Novartis AG | Antibody molecules to tim-3 and uses thereof |
| CN106255704A (zh) * | 2014-04-16 | 2016-12-21 | Ucb生物制药私人有限公司 | 多聚体Fc蛋白 |
| SG10201912986PA (en) * | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| AU2015269415A1 (en) * | 2014-06-05 | 2017-01-05 | The Board Of Trustees Of The University Of Arkansas | Antibody guided vaccines and methods of use for generation of rapid mature immune responses |
| MY189836A (en) * | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP6668345B2 (ja) * | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| BR112018010172A2 (pt) * | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| CN108623686A (zh) | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
| JP7836088B2 (ja) * | 2019-12-03 | 2026-03-26 | 上海交通大学医学院 | ＦｃγＲＩＩＢ親和性が増強された抗体Ｆｃ領域 |
| CR20220582A (es) * | 2020-05-01 | 2023-01-09 | Bolt Biotherapeutics Inc | Anticuerpos anti-dectina-2 |
| CN114106174A (zh) * | 2020-08-27 | 2022-03-01 | 苏州景涞医疗科技有限公司 | 低毒性抗ox40抗体、其药物组合物及应用 |
-
2017
- 2017-06-08 WO PCT/CN2017/087620 patent/WO2017211321A1/zh not_active Ceased
- 2017-06-08 JP JP2019517135A patent/JP2019528082A/ja active Pending
- 2017-06-08 EP EP17809760.6A patent/EP3470424B1/en active Active
- 2017-06-08 US US16/308,156 patent/US12145993B2/en active Active
- 2017-06-08 CN CN201710429281.6A patent/CN107474136B/zh active Active
- 2017-06-08 CN CN202210729123.3A patent/CN115304669A/zh active Pending
-
2021
- 2021-05-26 JP JP2021088589A patent/JP2021143186A/ja active Pending
-
2024
- 2024-05-29 JP JP2024087108A patent/JP7809372B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528082A5 (https=) | ||
| JP7809372B2 (ja) | アゴニスト抗体の活性を増強する抗体重鎖定常領域配列 | |
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| US12029761B2 (en) | Guidance and Navigation Control proteins and method of making and using thereof | |
| JP2020530289A5 (https=) | ||
| JP2020521452A (ja) | 標的化免疫寛容 | |
| CA3174097A1 (en) | T-cell modulatory polypeptides with conjugation sites and methods of use thereof | |
| JP2017524367A5 (https=) | ||
| JP2018512430A5 (https=) | ||
| JP2023541771A (ja) | リガンド－受容体対及び生物学的に機能的なタンパク質を含む融合タンパク質 | |
| JP2017533207A5 (https=) | ||
| CN121779568A (zh) | 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途 | |
| CA3058262A1 (en) | Chimeric polypeptides and methods of altering the membrane localization of the same | |
| JP2023515196A (ja) | 脂肪酸分子とコンジュゲートされた抗体及びその使用 | |
| JPWO2020006374A5 (https=) | ||
| CN115515981A (zh) | 抗肿瘤相关抗原抗体及其用途 | |
| WO2023147331A1 (en) | Bispecific molecule with tunable affinity to a targetted antigen | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| WO2023177974A2 (en) | Anti-mesothelin antibodies and uses thereof | |
| AU2023218343A1 (en) | Anti-il13ra2 antibodies and uses thereof | |
| KR20250102074A (ko) | 항-5t4 항체 및 이의 용도 | |
| CN120187757A (zh) | 抗EGFRvIII抗体及其用途 | |
| WO2024182475A2 (en) | Anti-ror2 antibodies and uses thereof | |
| WO2024076864A2 (en) | Anti-ror1 antibodies and uses thereof | |
| HK40127603A (zh) | 抗egfrviii抗体及其用途 |